Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > NASDAQ

<< Previous

Bullboard Posts

Next >>

Comment by Arbourmarkon Mar 24, 2021 9:23am

118 Views

Post# 32865255

RE:RE:RE:RE:NASDAQ

Walkover,

Can you explain to me how a stock on the TSX big board is easily manipulated but by simply listing on large US board like Nasdaq or NY will instantly raise SP to $6-15.

If you think shortens are manipulating here, trust me they are sharks there.

In my opinion the sp is where it is because of lack of news and lack of volume. Once we get news we will get volume and sp will take care of itself.

I think listing on US exchange is dangerous until we have strong share price above $10 as we would currently barely meet minimum US exchange price risking another reverse consolidation to get price up.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario